Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported fourth-quarter earnings of $72 million. On a per-share basis, the Princeton, New Jersey-based ...

Business Editor Alan Healy reports on Ireland's enduring appeal as a location for US firms to set up shop — despite a ...

Bristol Myers Squibb ... safety profile with no new safety signals. The study also met the key secondary endpoint of complete response rate. Bristol Myers Squibb said this study marks the fifth ...

Bristol Myers Squibb will cut $2 billion in costs by the ... allowing the company to invest in new drugs and research. The company previously outlined plans to cut $1.5 billion by 2025, which ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19 ... and there is a need for new effective and tolerable treatment options to address this unmet critical need ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Qorvo ...

Karuna’s crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.